For more information on studies being conducted at the WRAIR
to send a confidential email to one of our recruiters.
Marburg Vaccine Study #2438
What is Marburg virus? Marburg virus is a viral infection that was first recognized in 1967. Marburg virus belongs to the same family of viruses as the Ebola virus. Currently there are no approved vaccines or therapeutics to treat individuals infected with Marburg virus.
What does this study involve? This study involves an experimental Marburg virus vaccine. If you choose to participate in this study, you will receive one vaccination, given into the muscle of your upper arm using a needle and syringe. You will then be asked to return to the clinic for 8 additional visits throughout the 48 week study duration. This study’s primary purposes are to look at the safety of the vaccine and the ability of your body to produce antibodies. All study volunteers will be paid for their participation in this study.
NOTE: You CANNOT become infected with the Marburg virus by receiving this vaccine.
for more information on our Marburg vaccine study.
NOTE: There may be other reasons why you cannot participate in this study.
Study Setting: Outpatient
Study Duration: 48 weeks (approx 11 months)
Number of Visits: 9 clinic visits + 1 phone call
Study Start: Enrollment for group 1 will begin late September/early Oct 2018
Screening Dates: weekday mornings between 6:00am & 10:00am*
- *Please call 1-866-428-2788 to schedule a screening appointment
To be eligible for this study, you:
be 18 to 50 years of age
be in good general health without clinically significant medical history
have a body mass index (BMI) <40
(this is a calculation based on your height and weight)
be available to attend follow-up visits through 48 weeks after vaccination
have a valid U.S. government-issued or state-issued photo ID
(such as a driver's license, military ID, or U.S. passsport)
be willing and able to provide a personal cell phone number or
home phone number at which you can be reliably contacted
have received any other investigational Ebola or Marburg vaccines in a prior
clinical trial or cAd3-based vaccine in the past.
be pregnant, breastfeeding, or planning on becoming
pregnant for 6 months after receiving the study vaccine. For safety reasons,
females must also agree to use an effective form of birth control from at least
21 days prior to enrollment until at lease 6 months after receiving the study vaccination.
✘CANNOT have a history
of any of the following clinically significant conditions:
✔ Serious allergic reaction to vaccines or allergic reaction to drugs like
gentamycin, neomycin or streptomycin
✔ Autoimmune disease or immunodeficiency or chronically recurring hives, asplenia
(lack of normal spleen function) or a history of angioedema (facial swelling)
✔ HIV infection
✔ Active sypyilis infection
✔ Diabetes mellitus (type I or II)
✔ Thyroid diesease that is not well controlled
✔ High blood pressure or asthma that is not well controlled
✔ Bleeding problem or disorder
✔ Cancer that is active, currently being treated, or not surgically cured
✔ Seizure in the past 3 years or treatment for seizure disorder in the past 3 years
✔ Any current or past medical, psychiatric, or social condition that may interfere
with your full participation in the study or that may impair your ability to provide
informed consent as determined by the study physician
✘CANNOT have received any of the following:
✔ Drugs that may modify your immune system within 14 days prior to enrollment
such as prednisone or dexamethasone
✔ Blood products within 112 days (16 weeks) prior to enrollment
✔ Any “live-attenuated” vaccine (e.g., oral polio, yellow fever, measles, etc.)
within 28 days prior to enrollment in the present study or any other vaccine
within 14 days prior to enrollment
✔ Experimental research drugs or vaccines within 28 days prior to enrollment in the present study
✔ Drugs for treating or preventing Tuberculosis
If you are not interested in or do not meet the eligibility criteria to participate in our Marburg vaccine study, but would like to be added to a waiting list for future research study opportunities at the WRAIR CTC, please click here and provide us with the following information:
✔Your preferred method of contact (phone, email or text message)
✔The best time to contact you (morning or afternoon)
✔How you heard about our studies
The Clinical Trials Center Team
Call: 866-4-CTC-STUDY (866-428-2788)
Business Hours: Monday-Friday, 6:00am-2:30pm
This page last updated on: 29 Aug 2018